NEW YORK, Aug. 10, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nymox Pharmaceutical Corporation ("Nymox" or the "Company") (NASDAQ: NYMX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
The investigation concerns whether Nymox and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On August 10, 2016, Seeking Alpha published an article entitled "Nymox: This Offshore 'Biotech' Promotion Will Go To Zero (Yes, Zero)", reporting that Nymox management has consistently misled shareholders about the Company's prospects while "aggressively dump[ing] stock without timely SEC disclosure."
On this news, Nymox stock has fallen as much as $1.47, or 47.27%, to $1.64 during intraday trading on August 10, 2016.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
SOURCE Pomerantz LLP